SCHEMBL30714565

SCHEMBL30714565

Cn1nc2ccc(OCc3ccccc3)cc2c1C(=O)NC1CCN(CCO)C1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 2/20 0.44
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
SRC P12931 1/20 0.39
XIAP P98170 1/20 0.39
RIPK1 Q13546 2/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNA5 P30532 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
NMT1 P30419 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
KCNH2 Q12809 1/20 0.38
MCHR1 Q99705 1/20 0.38
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714573 0.90 MET (0.40) HTR3AKDM4EALDH1A1
SCHEMBL30714705 0.90 MET (0.40) HTR3AKDM4EALDH1A1
SCHEMBL30714689 0.87 HPGDS (0.35) HTR3ASRCRIPK1KDM4EALDH1A1
SCHEMBL30714675 0.85 SCN9A (0.35) HTR3AXIAPRIPK1KDM4EALDH1A1
SCHEMBL31539871 0.84 SCN9A (0.35) HTR3ASRCRIPK1KDM4EALDH1A1
SCHEMBL30714676 0.82 APOL1 (0.49) HTR3AMAOAMAOBNMT1KCNH2
SCHEMBL30714713 0.80 HTR3A (0.51) HTR3AMAOAMAOBMCHR1
SCHEMBL30714693 0.76 HTR3A (0.47) HTR3AMAOAMAOBNMT1KDM4E
SCHEMBL26696088 0.76 SRD5A2 (0.50) MAOBNMT1
SCHEMBL30714748 0.75 HTR3A (0.43) HTR3ANMT1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 HTR3A 62/4885MAOA 1535/4885MAOB 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.